UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

CorMedix-- Lohn sich noch ein Einstieg?

Seite 1 von 1
neuester Beitrag: 08.07.19 10:16
eröffnet am: 15.03.19 11:52 von: centsucher Anzahl Beiträge: 9
neuester Beitrag: 08.07.19 10:16 von: Requester Leser gesamt: 1198
davon Heute: 2
bewertet mit 1 Stern

2794 Postings, 2169 Tage centsucherCorMedix-- Lohn sich noch ein Einstieg?

 
  
    
1
15.03.19 11:52

2794 Postings, 2169 Tage centsucherQ4 vom 14.3 19

 
  
    
15.03.19 16:27

RS : become effective before trading opens on March 26, 2019,

es a result of the reverse stock split, the number of shares of common stock issued and outstanding will be reduced from approximately 119.0 million to approximately 23.8 million shares. There will be no change to the number of authorized shares.


Recent Corporate and Clinical Highlights:

--Announced statistically significant topline results of the interim analysis and full data set of its Phase 3 LOCK-IT-100 Study in Neutrolin.

The full data set showed a 71% reduction in the risk of occurrence of CRBSIs compared with the active control of heparin, which is well in excess of the study's assumed treatment effect size of a 55% reduction and statistically significant with a p-value of 0.0006.

-- Cash at December 31, 2018 amounted to $17.6 million


Now that our cash position has been strengthened and we anticipate that existing cash can fund us into the second quarter of 2020, we believe we are well positioned to make significant progress during 2019

Fourth Quarter 2018 Financial Highlights

For the fourth quarter 2018, CorMedix recorded a net income of $2.2 million, or $0.02 per share, compared with a net loss of $10.3 million, or $0.15 per share in the fourth quarter 2017, an increase of $12.5 million. The significant improvement in the fourth quarter 2018 was primarily driven by the reversal of clinical trial expenses as a result of the confidential settlement agreement with our CRO signed in November 2018.

Operating expenses in the fourth quarter 2018 recorded a gain of $2.1 million, compared to an expense of $10.4 million in the fourth quarter of 2017, a decrease of approximately 120%. This decrease was due primarily to a $12.8 million, or 151% decrease, in R&D expense, while SG&A expenses remained unchanged.

Full-Year 2018 Financial Highlights

For the full-year 2018, CorMedix recorded a net loss of $26.8 million, or $0.30 per share, compared with a net loss of $32.9 million, or $0.60 per share for the full-year 2017. The decrease in the loss in 2018 was primarily driven by decreased costs related to the LOCK-IT-100 clinical study.

Operating expenses for the full-year 2018 were $26.9 million, compared to $33.1 million for the full-year 2017, a decrease of approximately 19%. This decrease was due primarily to a $5.7 million, or 23% decrease, in R&D expense, while SG&A expenses remained unchanged.

 

2794 Postings, 2169 Tage centsucherAch du Alarm!!

 
  
    
15.03.19 22:19

  The number of outstanding shares of the registrant?s common stock was 119,014,093 as of March 12, 2019.

Da stehen noch über 40 Mio Aktien, fast alle im Geld! Das werden mit Sicherheit noch mehr, wenn die sich untereinander verdünnen.

BIN DANN MAL WEG!!!!!!!!!



As of December 31, 2018, we had outstanding the following securities that are convertible into or exercisable for shares of our common stock:
 
?
options to purchase an aggregate of 120,000 shares of our common stock issued to our officers, directors, employees and non-employee consultants under our Amended and Restated 2006 Stock Incentive Plan, or the 2006 Stock Plan, with a weighted average exercise price of $1.44 per share;
?
options to purchase an aggregate of 4,936,326 shares of our common stock issued to our officers, directors and non-employee consultants under our 2013 Stock Plan, with a weighted average exercise price of $1.87 per share;
?
warrants for 500,000 shares of common stock issued in May 2013 with an exercise price of $0.001 per share that expire on May 30, 2019;
?
warrants for 750,000 shares of common stock with an exercise price of $0.001 that expire on October 22, 2019;
?
warrants for 725,000 shares of common stock with an exercise price of $0.90 that expire on January 8, 2020;
?
Series C-2 Preferred Stock convertible into 1,500,000 shares of common;
?
Series C-3 Preferred Stock convertible into 1,040,000 shares of common stock;
?
Series D Preferred Stock convertible into 1,479,240 shares of common stock;
?
Series E Preferred Stock convertible into 1,959,759 shares of common stock;
?
Series F Preferred Stock convertible into 12,345,679 shares of common stock, subject to adjustment;
?
warrants for 682,500 shares of common stock issued in March 2014 with an exercise price of $2.50 per share that expire on September 10, 2019;
?
warrants for 200,000 shares of common stock with an exercise price of $7.00 that expire on March 3, 2020;
?
warrants for 83,400 shares of common stock with an exercise price of $7.00 that expire on March 25, 2020;
?
Series B warrants for 11,974,839 shares of common stock with an exercise price of $1.05 that expire on August 10, 2022;
?
underwriter warrants for 664,419 shares of common stock with an exercise price of $0.9375 that expire on August 10, 2022;
?
warrants for 564,858 shares of common stock with an exercise price of $0.001 that expire on November 16, 2020;
?
warrants for 450,000 shares of common stock with an exercise price of $1.50 that expire on December 31, 2023;
?
Senior convertible note convertible into 5,000,000 shares of common stock; and
?
restricted stock units for 29,087 shares of common stock with an average grant date fair value of $2.08 per share.

 

2794 Postings, 2169 Tage centsucherDumm gelaufen!

 
  
    
1
26.03.19 16:37
Der Einszieg hätte sich geringfügig gelohnt! ;-))) Heul!!!  

2794 Postings, 2169 Tage centsucherAch, war nur der RS!

 
  
    
26.03.19 20:33
Doch alles richtig gemacht.  

3791 Postings, 277 Tage Gonzodererstewas ist da passiert

 
  
    
1
01.04.19 23:03
das der Kurs so explodiert?

Zahlen habe ich keine gefunden....  

22 Postings, 675 Tage Requester1 zu 5 Reverse Split

 
  
    
1
02.04.19 12:03
Alle warten auf NDA, danach Fast Track (bedeutet ca. 6 Monate) bis zum möglichen FDA Approval  

2794 Postings, 2169 Tage centsucherQ1 am 13.5

 
  
    
08.05.19 21:00
Upcoming Events

CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update
May 13 ? 4:30pm ET, 2019
Click Here for Webcast  

22 Postings, 675 Tage RequesterHallo zusammen,

 
  
    
08.07.19 10:16
kurze Frage. Würdet ihr bei positiven NDA verkaufen (sell the news) oder halten und auf FDA Approval spekulieren ? Oder vielleicht Teilverkauf bei NDA ? Danke  

   Antwort einfügen - nach oben